Business Information
The company's principal activities are to acquire, develop and commercialize proprietary pharmaceutical products for cancer patients. The products include salagen tablets, hexalen capsules, didronel iv infusion, palonosetron, irofulven, mg98, dna methyltransferase inhibitors and other acylfulvene analogs. Currently, the products are promoted in the United States directly to radiation oncologists, select medical oncologists, hematology oncologists, rheumatologists and internal medicine physicians, and other physician specialists. International markets for the products include Europe, Japan, Australia, Canada, Colombia, egypt, Hong Kong, Israel, Korea, Singapore, Malaysia and Taiwan.
|
|
Name |
Title
|
Email
|
| Hugh Miller | Chmn. | N/A | | Eric Loukas | Exec. VP, COO, Sec. | N/A | | Mary Hedley | Chief Scientific Officer, Exec. VP | N/A | | William Spengler | CFO, Exec. VP | N/A | | Andrew Ferrara | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 342,788 | (40,161) | | 2005 | 279,362 | (132,410) | | 2004 | 195,667 | (85,723)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
